258 related articles for article (PubMed ID: 24463215)
1. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
[TBL] [Abstract][Full Text] [Related]
2. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.
Schanz J; Tüchler H; Solé F; Mallo M; Luño E; Cervera J; Granada I; Hildebrandt B; Slovak ML; Ohyashiki K; Steidl C; Fonatsch C; Pfeilstöcker M; Nösslinger T; Valent P; Giagounidis A; Aul C; Lübbert M; Stauder R; Krieger O; Garcia-Manero G; Faderl S; Pierce S; Le Beau MM; Bennett JM; Greenberg P; Germing U; Haase D
J Clin Oncol; 2012 Mar; 30(8):820-9. PubMed ID: 22331955
[TBL] [Abstract][Full Text] [Related]
3. New recurrent balanced translocations in acute myeloid leukemia and myelodysplastic syndromes: cancer and leukemia group B 8461.
Walker A; Mrózek K; Kohlschmidt J; Rao KW; Pettenati MJ; Sterling LJ; Marcucci G; Carroll AJ; Bloomfield CD;
Genes Chromosomes Cancer; 2013 Apr; 52(4):385-401. PubMed ID: 23225546
[TBL] [Abstract][Full Text] [Related]
4. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
DiNardo CD; Garcia-Manero G; Pierce S; Nazha A; Bueso-Ramos C; Jabbour E; Ravandi F; Cortes J; Kantarjian H
Am J Hematol; 2016 Feb; 91(2):227-32. PubMed ID: 26799610
[TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine.
Jabbour E; Kantarjian H; O'Brien S; Kadia T; Malik A; Welch MA; Teng A; Cortes J; Ravandi F; Garcia-Manero G
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):592-6. PubMed ID: 23790798
[TBL] [Abstract][Full Text] [Related]
6. EVI1 induces myelodysplastic syndrome in mice.
Buonamici S; Li D; Chi Y; Zhao R; Wang X; Brace L; Ni H; Saunthararajah Y; Nucifora G
J Clin Invest; 2004 Sep; 114(5):713-9. PubMed ID: 15343390
[TBL] [Abstract][Full Text] [Related]
7. Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group.
Kirtek T; Chen W; Laczko D; Bagg A; Koduru P; Foucar K; Venable E; Nichols M; Rogers HJ; Tam W; Orazi A; Hsi ED; Hasserjian RP; Wang SA; Arber DA; Weinberg OK
Leuk Res; 2023 Jul; 130():107309. PubMed ID: 37210875
[TBL] [Abstract][Full Text] [Related]
8. Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival.
Sanford D; DiNardo CD; Tang G; Cortes JE; Verstovsek S; Jabbour E; Ravandi F; Kantarjian H; Garcia-Manero G
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):556-62. PubMed ID: 26141213
[TBL] [Abstract][Full Text] [Related]
9. [The role of SF3B1 mutations in EVI1-rearranged myeloid neoplasms].
Tanaka A
Rinsho Ketsueki; 2023; 64(10):1258-1265. PubMed ID: 37914237
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and classification of myelodysplastic syndromes.
Hasserjian RP; Germing U; Malcovati L
Blood; 2023 Dec; 142(26):2247-2257. PubMed ID: 37774372
[TBL] [Abstract][Full Text] [Related]
11. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
Haase D; Stevenson KE; Neuberg D; Maciejewski JP; Nazha A; Sekeres MA; Ebert BL; Garcia-Manero G; Haferlach C; Haferlach T; Kern W; Ogawa S; Nagata Y; Yoshida K; Graubert TA; Walter MJ; List AF; Komrokji RS; Padron E; Sallman D; Papaemmanuil E; Campbell PJ; Savona MR; Seegmiller A; Adès L; Fenaux P; Shih LY; Bowen D; Groves MJ; Tauro S; Fontenay M; Kosmider O; Bar-Natan M; Steensma D; Stone R; Heuser M; Thol F; Cazzola M; Malcovati L; Karsan A; Ganster C; Hellström-Lindberg E; Boultwood J; Pellagatti A; Santini V; Quek L; Vyas P; Tüchler H; Greenberg PL; Bejar R;
Leukemia; 2019 Jul; 33(7):1747-1758. PubMed ID: 30635634
[TBL] [Abstract][Full Text] [Related]
12. CircZBTB46 predicts poor prognosis and promotes disease progression of myelodysplastic syndromes and acute myeloid leukemia.
Li S; Zhao G; Wu W; Li N; Wang Q; Wang W; Song X; Wang X
Clin Exp Med; 2023 Dec; 23(8):4649-4664. PubMed ID: 37930606
[TBL] [Abstract][Full Text] [Related]
13. Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia.
Khan M; Cortes J; Qiao W; Alzubaidi MA; Pierce SA; Ravandi F; Kantarjian HM; Borthakur G
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e19-e25. PubMed ID: 29107583
[TBL] [Abstract][Full Text] [Related]
14. A primary pediatric acute myelomonocytic leukemia with t(3;21)(q26;q22): A case report.
Duan JX; Liu F; Chang L; Che GL; Yang QX; Teng J; Jian H; Liu XJ; Lai SY
Medicine (Baltimore); 2023 Oct; 102(43):e35721. PubMed ID: 37904382
[TBL] [Abstract][Full Text] [Related]
15. Cytogenetics and molecular genetics of myelodysplastic neoplasms.
Ning Y; Zhang Y; Kallen MA; Emadi A; Baer MR
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101512. PubMed ID: 38092472
[TBL] [Abstract][Full Text] [Related]
16. The impact of category, cytopathology and cytogenetics on development and progression of clonal and malignant myeloid transformation in inherited bone marrow failure syndromes.
Cada M; Segbefia CI; Klaassen R; Fernandez CV; Yanofsky RA; Wu J; Pastore Y; Silva M; Lipton JH; Brossard J; Michon B; Abish S; Steele M; Sinha R; Belletrutti M; Breakey V; Jardine L; Goodyear L; Sung L; Shago M; Beyene J; Sharma P; Zlateska B; Dror Y
Haematologica; 2015 May; 100(5):633-42. PubMed ID: 25682607
[TBL] [Abstract][Full Text] [Related]
17. Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes.
Kwon A; Weinberg OK
Clin Lab Med; 2023 Dec; 43(4):657-667. PubMed ID: 37865509
[TBL] [Abstract][Full Text] [Related]
18. TP53 status and impact on AML prognosis within the ELN 2022 risk classification.
Fleming S; Tsai XC; Morris R; Hou HA; Wei AH
Blood; 2023 Dec; 142(23):2029-2033. PubMed ID: 37647854
[TBL] [Abstract][Full Text] [Related]
19. When to use which molecular prognostic scoring system in the management of patients with MDS?
Kewan T; Bewersdorf JP; Gurnari C; Xie Z; Stahl M; Zeidan AM
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101517. PubMed ID: 38092484
[TBL] [Abstract][Full Text] [Related]
20. Prognostic mutation constellations in acute myeloid leukaemia and myelodysplastic syndrome.
Iacobucci I; Mullighan CG
Curr Opin Hematol; 2021 Mar; 28(2):101-109. PubMed ID: 33427759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
